Pricing Manager

Morris & Dickson completes transaction to acquire Prodigy Health. For immediate release. Morris & Dickson completes transaction to acquire Prodigy Health expands specialty and plasma capabilities to support hospitals, clinics and alternative sites of care nationwide. January 26, 2026 - Shreveport, La. - Morris & Dickson ("M&D"), the nation's largest independent wholesale and specialty pharmaceutical distributor, today announced the successful completion of the acquisition of Prodigy Health, a specialty pharmaceutical distribution and services company. The transaction strengthens Morris & Dickson's specialty portfolio and expands access to plasma-derived therapies, while ensuring continuity, compliance and uninterrupted service for healthcare providers nationwide. The addition of Prodigy Health's capabilities enhances Morris & Dickson's ability to support hospitals, specialty pharmacies, clinics, infusion centers and alternative sites of care as demand for specialty and plasma therapies continues to grow. For manufacturers, the combination creates a broader, independent distribution platform with expanded reach, disciplined specialty capabilities and a compliance-first operating model. "This transaction reflects our long-term commitment to specialty distribution and alternative sites of care," said Jody Hatcher, chief executive officer of Morris & Dickson. "Our focus is on expanding access to critical therapies while preserving continuity for customers and operating with regulatory integrity that is consistent with our independent, customer-first values." "This is a meaningful step forward in our specialty strategy," said Layne Martin, head of specialty at Morris & Dickson. "By bringing Prodigy Health's purpose-built plasma and specialty expertise into the Morris & Dickson family, we are strengthening our ability to support complex therapies while maintaining the service and compliance our customers expect. Our immediate focus is disciplined execution and personalized customer support." As part of the transaction, Morris & Dickson will begin a phased integration process using a structured transition services model consistent with industry-specific best practices and applicable regulatory requirements. Operating as ProdigyMD, this approach is designed to maintain stability, allowing customers and manufacturers to benefit from expanded capabilities without disruption. For customers, this means uninterrupted ordering, fulfillment and support while Morris & Dickson works to integrate Prodigy Health's plasma and specialty tools to make them available to its broader customer base. For manufacturers, this transaction expands access to a broader, independent distribution platform with the scale and specialty focus required to support complex therapies. "By combining Morris & Dickson's national reach with Prodigy Health's specialty and plasma expertise, we are creating a reliable channel that helps manufacturers reach diverse sites of care while maintaining the service levels and regulatory integrity they expect," said Jason Hanks, chief commercial officer of Morris & Dickson. Effective immediately, Prodigy Health employees will become part of the Morris & Dickson family. About Morris & Dickson Founded in 1841 and headquartered in Shreveport, Louisiana, Morris & Dickson is an independent full-line and specialty pharmaceutical distributor serving health systems, independent pharmacies, clinics, infusion centers, and alternative care facilities nationwide. The company combines next-day delivery, automated distribution, and a broad pharmaceutical portfolio to support safe, reliable care across the United States. www.morrisdickson.com About ProdigyMD ProdigyMD, a Morris & Dickson company, is the successor to Prodigy Health and provides healthcare providers with access to plasma-derived products and specialty pharmaceutical therapies. Established in 2001 in Austin, Texas as Prodigy Health, the organization built a strong reputation for specialized expertise, personalized service and trusted customer relationships. ProdigyMD continues this legacy while operating as part of Morris & Dickson's specialty distribution platform, supporting hospitals, clinics, infusion centers, and alternative sites of care nationwide. https://prodigy.morrisdickson.com

Morris & Dickson to acquire fellow pharma distributor Prodigy Health. Prodigy is a specialty distributor of plasma derivatives, specialty drugs and vaccines based in Shreveport, LA. Pharmaceutical distributor Morris & Dickson, headquartered in Shreveport, LA, signed a non-binding Letter of Intent (LOI) to acquire Prodigy Health - a privately held, national specialty distributor of plasma derivatives, specialty drugs and vaccines. In a Dec. 8 news release, the company said the proposed acquisition of Austin, TX-based Prodigy Health underscores Morris & Dickson's accelerated growth in serving both inpatient and outpatient care settings for health systems, hospitals and provider-owned community clinics and infusion centers. With the acquisition, M&D will expand its product portfolio to include a comprehensive on-shelf inventory of plasma derivatives, coagulation products, immune globulin, recombinants and vaccines for both acute and non-acute care. All will be available through one company and one ordering portal, supported by M&D's distribution services and account support team. Prodigy Health customers will also gain access to 30,000 SKUs of full-line and specialty products through the M&D portfolio, plus the strength of an independent organization with 180-plus years of serving pharmacies. "Signing the LOI with Prodigy Health is another important step in our growth strategy as we continue to expand nationally in support of pharmacies across all sites of care," Morris & Dickson CEO Jody Hatcher said. "The Prodigy team has built extensive capabilities in the management of these high-cost drugs for bleeding disorders and immune deficiencies, and they are aligned to our goal of creating an alternative, more agile and responsive distribution solution for pharmacies. This acquisition underscores our ability to serve customers in a more meaningful way with our full focus on their pharmacy success." Transaction terms were not disclosed and deal close is anticipated in Q1 2026. Both organizations will operate independently upon completion.

Mark Cuban Cost Plus Drug Company collaborates with Morris & Dickson for medication access.